Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering

Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that...

Kazia closes oversubscribed offering to fund paxalisib’s clinical development

Kazia Therapeutics has closed an oversubscribed public offering that could provide the company with up to $120m in gross proceeds if all milestone-linked warrants are exercised, aimed primarily at funding clinical development of paxalisib. The post Kazia closes oversubscribed offering to fund paxalisib’s clinical development appeared first on Hospital Management.